Leeds, 06 December 2016 – Tissue Regenix Group (AIM:TRX) (“Tissue Regenix” or “The Group”) the regenerative medical devices company today announces Tissue Regenix Wound Care, Inc. has secured a Group Purchasing Organisation (GPO) contract with Premier Inc., a leading healthcare improvement company.
DermaPure has been awarded this contract under a ‘Breakthrough Technology Agreement’, which is awarded by the GPO after a thorough four step review process is completed and it is determined that the technology offers unique attributes to the other available treatment options.
The Premier alliance is comprised of approximately 3,600 U.S. based hospitals and 120,000 other healthcare providers which will now have contracted access to DermaPure®.
Antony Odell, CEO, Tissue Regenix Group plc commented: “Approval under Premier’s Breakthrough Technology Agreement marks a significant milestone for DermaPure®. This confirms the unique characteristics of our patented dCELL® Technology, the powerful clinical evidence we have collected, and the remarkable outcomes it achieves in real world clinical situations.”
For more Information:
|Tissue Regenix Group plc
Corporate Communications Officer
|Tel: 0330 430 3073|
|Jefferies International Ltd
Simon Hardy / Harry Nicholas
|Tel: 020 7029 8000|
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company’s patented decellularisation (‘dCELL®’) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States – ‘Tissue Regenix Wound Care Inc.’, as part of its commercialisation strategy for its dCELL® technology platform.